Seattle Genetics, Inc. (SGEN)
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
Recs
antibodies and their conjugates are the future of cancer therapeutics
Recs
Partnered well with funding and a intriguing pipeline.
Recs
Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
Chart pattern indicates a Strong Upward Trend.
Relative Strength is Bullish.
Up/Down volume pattern indicates that the stock is under Accumulation.
The 50 day Moving Average is rising which is Bullish.
The 200 day Moving Average is rising which is Bullish.
Look for Support at 9.89
Watch for resistance at 10.84
Recs
Great biotech with a great pipeline and money
Recs
Oversold (but then again, what isn't?!)
Recs
I like the Hodgkins drug.
Recs
Great cancer research stock. Think in 2-4 years will be well past its recent 52 week high of 13.44
Recs
Biopharmaceuticals are being valued at a premium and Seattle Genetics has the goods. Is it the blood cancer biologics version of solid tumor small molecule Exelixis?
Recs
HAS INTRODUCED A CLENICAL TRIAL FOR SGN-33 TREATMENT OPTION FOR MDS
Recs
Over the next 3 years look for Seattle Genetics to develop and more that triple in price with new forms of rev and more earnings than expected.
Recs
it going up and we cant do nothing about
Recs
Biotech is the future and this group has some great innovations and brilliant management staff.
Recs
Drugs, death, live forever, more drugs, bald men, angry women, everything is controled on drugs...you need a biotech company in your port...who knows what they will discover today...what cure is next and who is going to hit on it...there are many bald men out there waiting.
Recs
good internals, great partners, possible acquisition target
Recs
Recs
Seattle Genetics is a solid Biotech company with outstanding potential. The insider buying has been great as they are very near Phase III trials. One year sales growth is 99.70% and Genetics is the future for medicine. Although Baby-Boomers are giving great potential to any drug company, as with all Biotech we still need a product to succeed.
Recs
great drug line,insider buying strong.they are nearing ph3 trials
Recs
Innovator of Monoclonal Antibody based drugs
Recs
insiders
Recs
It's a risk, but I'm thinking that genetics and their new drugs in trial will possibly pull through.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 45 1 2 3 Next »